Assessment of serum prolidase levels in patients with coronary artery in-stent restenosis: Serum prolidase levels in stent restenosis

Basit Öğe Kaydı
dc.authorid0000-0002-3183-5815en_US
dc.authorid0000-0002-6913-9073en_US
dc.contributor.authorMemioğlu, Tolga
dc.contributor.authorAyhan, Selim
dc.contributor.authorDönmez, İbrahim
dc.date.accessioned2023-06-09T07:33:04Z
dc.date.available2023-06-09T07:33:04Z
dc.date.issued2021en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractAim: Prolidase is an enzyme, which plays a role in the formation of a new matrix, collagen metabolism and cell development. It is known that the most Important mechanism underlying in-stent restenosis is neointimal hyperplasia. Neointimal hyperplasia is associated with collagen synthesis and matrix proteins. The objective of our study was to reveal the relationship between serum prolidase levels and in-stent restenosis. Material and Methods: This study included a total of 70 patients who were identified to be at a moderate and high risk as a result of clinical or non-invasive tests in the cardiology and emergency clinics of the Abant Izzet Baysal University training and Research Hospital and who underwent angiography. In-stent restenosis was identified in 40 patients. In the remaining 30 patients, there was no angiographically determined critical lesion. Serum prolidase levels were measured in all patients. Results: The mean serum level of prolidase was found to be statistically significantly higher in the in-stent restenosis group compared to the restenosis-free group (p=0.02). The mean serum level of prolidase level was significantly higher in smokers compared to the non-smoker patients (p=0.04). It was observed that serum prolidase levels statistically significantly increased proportionally to the in-stent restenosis percentage (p=0.04). Discussion: The results of this study indicate that prolidase enzyme levels may enable timely and correct assessment of in-stent restenosis, and may contribute to the decision for changing the treatment or timing to increase the intensity of the treatment in patients undergoing percutaneous coronary intervention (PCI) with coronary stenting.en_US
dc.identifier.doi10.4328/ACAM.20689
dc.identifier.endpage1202en_US
dc.identifier.issn2667-663X
dc.identifier.issue11en_US
dc.identifier.startpage1198en_US
dc.identifier.urihttps://www.webofscience.com/wos/woscc/full-record/WOS:000732422900001
dc.identifier.urihttps://hdl.handle.net/20.500.12491/11091
dc.identifier.volume12en_US
dc.identifier.wosWOS:000732422900001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorDönmez, İbrahim
dc.language.isoenen_US
dc.publisherBayrakol Medical Publisheren_US
dc.relation.ispartofAnnals of Clinical and Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPercutaneous Interventionen_US
dc.subjectCoronary Stenten_US
dc.subjectIn-Stent Restenosisen_US
dc.subjectProlidaseen_US
dc.titleAssessment of serum prolidase levels in patients with coronary artery in-stent restenosis: Serum prolidase levels in stent restenosisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
tolga-memioglu.pdf
Boyut:
319.13 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu